Literature DB >> 11072156

Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix.

A D Santin1, P L Hermonat, A Ravaggi, S Bellone, J Roman, S Pecorelli, M Cannon, G P Parham.   

Abstract

PURPOSE: To compare the effects of concurrent administration of cisplatinum (40 mg/m(2)/weekly) with radiation therapy (C-RT) to those induced by radiation therapy alone (RT) on the immune function of patients with locally advanced cervical cancer. METHODS AND MATERIALS: In 8 prospectively randomized patients (i.e., 4 receiving RT vs. 4 receiving C-RT), lymphocyte populations including CD3+, CD4+ and CD8+ T-cell subsets, B cells (CD19+) and natural killer cells (CD56+, CD16+, CD3-) were studied before, during, and after therapy. Expression of the activation marker CD25 on CD3+ T cells, intracellular levels of perforin in CD8+ and CD56+ cells, and interferon-gamma (IFN-gamma) and IL-2 in CD4+ and CD8+ T cells was also measured. Finally, lymphoblast transformation and natural killer (NK) cytotoxic activity were assessed.
RESULTS: Both RT and C-RT significantly decreased the mean absolute number of all lymphocyte subsets compared to pretreatment levels (p > 0.001). However, no differences were detected in the characteristics or the magnitude of the lymphopenia induced by the two treatments. Both RT and C-RT increased similarly the percentages of CD25-positive lymphocytes (p > 0.001), and significantly decreased PHA-induced T-cell lymphoblast transformation (p > 0.001) and NK cytotoxic activity against K562 cells (p > 0.001). The percentage of perforin-positive and CD8+ T cells was not altered during either treatment, whereas the percentage of perforin-positive and CD56+ cells was significantly reduced during both treatments, and correlated with reduced cytotoxicity against K562 cells. The percentages of CD8+ IFN-gamma+ and CD4+ IFN-gamma+ T cells as well as that of CD8+ IL-2+ and CD4+ IL2+ T cells were not significantly altered by C-RT compared to RT alone. Finally, with both regimens, NK cells and B-cell numbers showed a more rapid recovery than T-cell numbers.
CONCLUSION: Administration of concurrent cisplatinum to radiation may synergistically increase cytotoxic effects of radiation on tumor cells but does not alter the magnitude and the characteristics of radiation-induced immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072156     DOI: 10.1016/s0360-3016(00)00769-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  24 in total

1.  Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach.

Authors:  Susan K Lutgendorf; Elizabeth Mullen-Houser; Daniel Russell; Koen Degeest; Geraldine Jacobson; Laura Hart; David Bender; Barrie Anderson; Thomas E Buekers; Michael J Goodheart; Michael H Antoni; Anil K Sood; David M Lubaroff
Journal:  Brain Behav Immun       Date:  2010-06-30       Impact factor: 7.217

2.  Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Authors:  Christine E Richter; Emiliano Cocco; Stefania Bellone; Marta Bellone; Francesca Casagrande; Paola Todeschini; Dominik Rüttinger; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Int J Gynecol Cancer       Date:  2010-12       Impact factor: 3.437

3.  Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Authors:  Alessandro D Santin; Michael W Sill; D Scott McMeekin; Mario M Leitao; Jubilee Brown; Gregory P Sutton; Linda Van Le; Patricia Griffin; Cecelia H Boardman
Journal:  Gynecol Oncol       Date:  2011-09       Impact factor: 5.482

4.  The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer.

Authors:  Makito Mizunuma; Yoshihito Yokoyama; Masayuki Futagami; Masahiko Aoki; Yoshihiro Takai; Hideki Mizunuma
Journal:  Int J Clin Oncol       Date:  2015-03-04       Impact factor: 3.402

Review 5.  Severe Radiation-Induced Lymphopenia Affects the Outcomes of Esophageal Cancer: A Comprehensive Systematic Review and Meta-Analysis.

Authors:  Dongjun Dai; Qiaoying Tian; Genhua Yu; Yongjie Shui; Hao Jiang; Qichun Wei
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

6.  Significant impairment in immune recovery after cancer treatment.

Authors:  Duck-Hee Kang; Michael T Weaver; Na-Jin Park; Barbara Smith; Traci McArdle; John Carpenter
Journal:  Nurs Res       Date:  2009 Mar-Apr       Impact factor: 2.381

7.  Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer.

Authors:  Oyeon Cho; Young-Taek Oh; Mison Chun; O Kyu Noh; Hyun-Woo Lee
Journal:  Tumour Biol       Date:  2015-08-12

8.  Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

Authors:  Alessandro D Santin; Stefania Bellone; Michela Palmieri; Alessandro Zanolini; Antonella Ravaggi; Eric R Siegel; Juan J Roman; Sergio Pecorelli; Martin J Cannon
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

9.  Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.

Authors:  Emiliano Cocco; Joyce Varughese; Natalia Buza; Stefania Bellone; Michelle Glasgow; Marta Bellone; Paola Todeschini; Luisa Carrara; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Charles J Lockwood; Alessandro D Santin
Journal:  BMC Cancer       Date:  2011-06-22       Impact factor: 4.430

10.  Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood.

Authors:  Jihane Boustani; Elodie Lauret Marie Joseph; Etienne Martin; Salim Benhmida; Benoit Lecoester; Florent Tochet; Céline Mirjolet; Cédric Chevalier; David Thibouw; Noémie Vulquin; Stéphanie Servagi; Xushan Sun; Olivier Adotévi
Journal:  BMC Immunol       Date:  2021-06-18       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.